As Senior Vice President, R&D Chief Operating Officer Nicholas Donoghoe oversees the operational and strategic execution of our pipeline across the R&D organization. In addition, Dr. Donoghoe leads the portfolio wide capability building that increase AbbVie’s agility, speed and cross-functional execution to unlock the full potential of our portfolio.
Dr. Donoghoe joined AbbVie in 2019 in a newly created Innovation role to support corporate growth through cross-functional efforts across the company. In 2020, he then led Global Strategy and Operations for Allergan Aesthetics with responsibility for pipeline marketing, customer service, analytics, and commercial strategy.
In 2021, Nicholas was asked to lead Portfolio Innovation across both the Aesthetics and Therapeutics businesses to define and implement transformational initiatives that directly impact short- and long-term goals and the future success of AbbVie.
Dr. Donoghoe views his work through a unique lens of business and scientific acumen, having served as a partner at McKinsey and holding an M.D. from Johns Hopkins University and a B.S. from Duke University. During his time at McKinsey, he served global clients across a broad range of geographies and therapeutic areas, including oncology, immunology, and neuroscience.